Pa. Justices To Mull Risperdal Breast-Growth Time Limit

Law360 (July 5, 2018, 7:12 PM EDT) -- In a pair of cases with implications for thousands of lawsuits pending in Philadelphia against a Johnson & Johnson unit, the Pennsylvania Supreme Court agreed on Thursday to weigh when the clock began to run on claims of abnormal breast growth in adolescent boys prescribed the antipsychotic drug Risperdal.

The appeal follows a November ruling by an intermediate appeals court finding that two plaintiffs in a mass tort program in Philadelphia County, which currently includes some 6,700 cases, should have known about the potential link between their abnormal breast growth and the powerful drug when a label for the medication was...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!